American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Anais brasileiros de dermatologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300355 |
Resumo: | Abstract: Pentavalent antimonials are the first-line drug treatment for American tegumentary leishmaniasis. We report on a patient with chronic renal failure on hemodialysis who presented with cutaneous lesions of leishmaniasis for four months. The patient was treated with intravenous meglumine under strict nephrological surveillance, but cardiotoxicity, acute pancreatitis, pancytopenia, and cardiogenic shock developed rapidly. Deficient renal clearance of meglumine antimoniate can result in severe toxicity, as observed in this case. These side effects are related to cumulative plasma levels of the drug. Therefore, second-line drugs like amphotericin B are a better choice for patients on dialysis. |
id |
SBD-1_982a396d5d59f7760c82dc07de788cf0 |
---|---|
oai_identifier_str |
oai:scielo:S0365-05962019000300355 |
network_acronym_str |
SBD-1 |
network_name_str |
Anais brasileiros de dermatologia (Online) |
repository_id_str |
|
spelling |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failureAmphotericin BKidney failure, chronicLeishmaniasisLeishmaniasis, cutaneousMegluminePancreatitisRenal insufficiency, chronicSkin ulcerAbstract: Pentavalent antimonials are the first-line drug treatment for American tegumentary leishmaniasis. We report on a patient with chronic renal failure on hemodialysis who presented with cutaneous lesions of leishmaniasis for four months. The patient was treated with intravenous meglumine under strict nephrological surveillance, but cardiotoxicity, acute pancreatitis, pancytopenia, and cardiogenic shock developed rapidly. Deficient renal clearance of meglumine antimoniate can result in severe toxicity, as observed in this case. These side effects are related to cumulative plasma levels of the drug. Therefore, second-line drugs like amphotericin B are a better choice for patients on dialysis.Sociedade Brasileira de Dermatologia2019-05-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300355Anais Brasileiros de Dermatologia v.94 n.3 2019reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1590/abd1806-4841.20198388info:eu-repo/semantics/openAccessMarques,Sílvio AlencarMerlotto,Maira RenataRamos,Paulo MüllerMarques,Mariangela Esther Alencareng2019-07-25T00:00:00Zoai:scielo:S0365-05962019000300355Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2019-07-25T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false |
dc.title.none.fl_str_mv |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure |
title |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure |
spellingShingle |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure Marques,Sílvio Alencar Amphotericin B Kidney failure, chronic Leishmaniasis Leishmaniasis, cutaneous Meglumine Pancreatitis Renal insufficiency, chronic Skin ulcer |
title_short |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure |
title_full |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure |
title_fullStr |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure |
title_full_unstemmed |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure |
title_sort |
American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure |
author |
Marques,Sílvio Alencar |
author_facet |
Marques,Sílvio Alencar Merlotto,Maira Renata Ramos,Paulo Müller Marques,Mariangela Esther Alencar |
author_role |
author |
author2 |
Merlotto,Maira Renata Ramos,Paulo Müller Marques,Mariangela Esther Alencar |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Marques,Sílvio Alencar Merlotto,Maira Renata Ramos,Paulo Müller Marques,Mariangela Esther Alencar |
dc.subject.por.fl_str_mv |
Amphotericin B Kidney failure, chronic Leishmaniasis Leishmaniasis, cutaneous Meglumine Pancreatitis Renal insufficiency, chronic Skin ulcer |
topic |
Amphotericin B Kidney failure, chronic Leishmaniasis Leishmaniasis, cutaneous Meglumine Pancreatitis Renal insufficiency, chronic Skin ulcer |
description |
Abstract: Pentavalent antimonials are the first-line drug treatment for American tegumentary leishmaniasis. We report on a patient with chronic renal failure on hemodialysis who presented with cutaneous lesions of leishmaniasis for four months. The patient was treated with intravenous meglumine under strict nephrological surveillance, but cardiotoxicity, acute pancreatitis, pancytopenia, and cardiogenic shock developed rapidly. Deficient renal clearance of meglumine antimoniate can result in severe toxicity, as observed in this case. These side effects are related to cumulative plasma levels of the drug. Therefore, second-line drugs like amphotericin B are a better choice for patients on dialysis. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-05-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300355 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962019000300355 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/abd1806-4841.20198388 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Dermatologia |
dc.source.none.fl_str_mv |
Anais Brasileiros de Dermatologia v.94 n.3 2019 reponame:Anais brasileiros de dermatologia (Online) instname:Sociedade Brasileira de Dermatologia (SBD) instacron:SBD |
instname_str |
Sociedade Brasileira de Dermatologia (SBD) |
instacron_str |
SBD |
institution |
SBD |
reponame_str |
Anais brasileiros de dermatologia (Online) |
collection |
Anais brasileiros de dermatologia (Online) |
repository.name.fl_str_mv |
Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD) |
repository.mail.fl_str_mv |
abd@sbd.org.br||revista@sbd.org.br |
_version_ |
1752126423415390208 |